Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company dedicated to tackling endocrine diseases and endocrine-related tumors. Their primary product candidate, Paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 agonist that has already completed its phase III clinical trial. The product is aimed at treating acromegaly and has also undergone a phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also in the process of developing CRN04777, another oral selective nonpeptide somatostatin type 5 receptor agonist, presently undergoing its phase I clinical trial. This product aims to help treat congenital hyperinsulinism. Additionally, CRN04894, an oral adrenocorticotrophic hormone antagonist, is currently undergoing its own phase I clinical trials. This product is aimed specifically for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was established in 2008 and has made its home in San Diego, California.